Abstract
This retrospective-medical-record review was conducted to evaluate effect of infliximab therapy, particularly with a ‘top-down’ strategy, on the nutritional parameters of children with Crohn’s disease (CD). 42 patients who were diagnosed with Crohn’s disease at the Pediatric Gastroenterology center of a tertiary care teaching hospital and achieved remission at two months and one year after beginning of treatment were divided into four subgroups according to the treatment regimen; ‘azathioprine’ group (n = 11), ‘steroid’ group (n = 11), infliximab ‘topdown’ group (n = 11) and ‘step-up’ group (n = 9). Weight, height, and serum albumin were measured at diagnosis, and then at two months and one year after the initiation of treatment. At 2 months, the Z-score increment for weight was highest in the ‘steroid’ group, followed by the ‘top-down’, ‘step-up’, and ‘azathioprine’ groups. At one year, the Z-score increment was highest in ‘top-down’ group, followed by ‘steroid’, ‘azathioprine’, and ‘step-up’ group. There were no significant differences between the four groups in Z-score increment for height and serum albumin during the study period. The ‘top-down’ infliximab treatment resulted in superior outcome for weight gain, compared to the ‘step-up’ therapy and other treatment regimens.
Similar content being viewed by others
References
Simon D. Inflammation and growth. J Pediatr Gastroenterol Nutr. 2010;51 (Suppl 3):S133–S134.
Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.
Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.
Summers RW, Switz DM, Sessions JT, Jr., Becktel JM, Best WR, Kern F, Jr., et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–869.
Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362.
IBD Working Group of the European Society for Paediatric Gastroenterology HaN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.
Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421.
Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn’s disease: which index to use? Gastroenterology. 1999;116:527–531.
Thayu M, Denson LA, Shults J, Zemel BS, Burnham JM, Baldassano RN, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn’s disease. Gastroenterology. 2010;139:430–438.
Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105:681–691.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, M.J., Lee, W.Y., Choi, K.E. et al. Effect of infliximab ‘Top-down’ therapy on weight gain in pediatric Crohn’s disease. Indian Pediatr 49, 979–982 (2012). https://doi.org/10.1007/s13312-012-0248-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0248-5